Form 4: Neurocrine Biosciences Officer David W. Boyer Reports Sale of Shares Under 10b5-1 Plan
SEC Form 4 Filing
David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 3,461 shares of common stock at an average price of $121.8804 under a pre-arranged 10b5-1 trading plan.
Summary
- On September 13, 2024, David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences Inc., sold 3,461 shares of common stock.
- The sale was executed under a Rule 10b5-1 trading plan adopted on June 14, 2024.
- The shares were sold at a weighted average price of $121.8804, with individual sales ranging from $120.31 to $122.48.
- Following the transaction, Boyer directly owns 1,672 shares of Neurocrine Biosciences common stock.
- This includes 238 shares purchased through the company's Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the officer's outlook on the company.
Industry Context
Sales by corporate officers are a normal part of corporate governance. Sales under a 10b5-1 plan are not as significant as discretionary sales as they are pre-planned.
Key Dates
| Date | Description |
|---|---|
| June 14, 2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| February 29, 2024 | Date of purchase of shares from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan |
| August 30, 2024 | Date of purchase of shares from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan |
| September 13, 2024 | Date of the stock sale transaction |
| September 17, 2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.